[Optimization of long-term hypolipidemia treatment of patients with myocardial infarction in combination with non-alcoholic steatohepatitis].
In a comparative aspect, the dynamics of indices of lipidogram, functional state of liver and level of C-reactive of protein have been analyzed in 79 patients with myocardial infarction in combination with non-alcoholic steatohepatitis, who received a 9-months treatment by rosuvastatin of 20 mg, atorvastatin of 80 mg, as well as rosuvastatin of 10 mg, atorvastatin of 40 mg in combination with ursodeoxycholic acid (UDCA). The obtained results show the equivalent of hypolipidemia effectiveness of all investigated courses of statinotherapy with the benefit of rosuvastatin of 20 mg in increase of level of HDL cholesterol and combined statinotherapy with UDCA in decrease of level of triglycerides. It was confirmed the significant advantages of combined statinotherapy with UDCA as for the influence on functional state of liver and CRP level, and advantages of rosuvastatin of 10 mg in combination with UDCA. Thus, the combination of rosuvastatin of 10 mg with UDCA should be preferable in the treatment of patients with myocardial infarction in combination with non-alcoholic steatohepatitis from the positions of the effectiveness and safety. Besides, taking into account positive correlation between the CRP level in blood and activity of transaminases in the dynamics of observation it can be concluded that high activity of transaminases is the prognostic marker of the severity and procession of polymorbid pathology - myocardial infarction in combination with non-alcoholic steatohepatitis.
D000069059:Atorvastatin; D001663:Bilirubin / Q000097:blood; D005464:Fluorobenzenes / Q000009:adverse effects / Q000627:therapeutic use; D006538:Heptanoic Acids / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000378:metabolism; D065626:Non-alcoholic Fatty Liver Disease / Q000188:drug therapy* / Q000378:metabolism; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use; D011758:Pyrroles / Q000009:adverse effects / Q000627:therapeutic use; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use; D000637:Transaminases / Q000097:blood; D014280:Triglycerides / Q000097:blood; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use
D005464:Fluorobenzenes; D006538:Heptanoic Acids; D000960:Hypolipidemic Agents; D008055:Lipids; D011743:Pyrimidines; D011758:Pyrroles; D013449:Sulfonamides; D014280:Triglycerides; D014580:Ursodeoxycholic Acid; D000068718:Rosuvastatin Calcium; D000069059:Atorvastatin; D000637:Transaminases; D001663:Bilirubin